Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Schizophrenia and split personality disorder.getty Cobenfy (xanomeline/trospium chloride; formerly KarXT) was approved for schizophrenia in adults by the Food and Drug Administration in late September. The drug has a novel mechanism of action, which is …